Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2 048
3 557.25
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one TORNTPHARM stock under the Base Case scenario is 1 952.77 INR. Compared to the current market price of 3 167.1 INR, Torrent Pharmaceuticals Ltd is Overvalued by 38%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Torrent Pharmaceuticals Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for TORNTPHARM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Torrent Pharmaceuticals Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Torrent Pharmaceuticals Ltd. has steadily carved a niche for itself as a formidable player in the global pharmaceutical landscape. Founded in 1959 in India, the company specializes in developing, manufacturing, and marketing a diverse portfolio of generic and branded formulations across therapeutic areas such as cardiovascular, central nervous system, and diabetology, among others. With a robust presence in over 40 countries and a strong focus on research and development, Torrent has established partnerships and collaborations that bolster its ability to innovate and expand its product offerings. The company’s commitment to quality and regulatory compliance is evident as it operates multiple...
Torrent Pharmaceuticals Ltd. has steadily carved a niche for itself as a formidable player in the global pharmaceutical landscape. Founded in 1959 in India, the company specializes in developing, manufacturing, and marketing a diverse portfolio of generic and branded formulations across therapeutic areas such as cardiovascular, central nervous system, and diabetology, among others. With a robust presence in over 40 countries and a strong focus on research and development, Torrent has established partnerships and collaborations that bolster its ability to innovate and expand its product offerings. The company’s commitment to quality and regulatory compliance is evident as it operates multiple state-of-the-art manufacturing facilities certified by global regulatory bodies, ensuring that their products meet the highest international standards.
For investors, Torrent Pharmaceuticals presents a compelling opportunity characterized by steady growth and a focus on long-term value creation. In recent years, the company has demonstrated resilience despite market challenges, driven by a growing demand for affordable medicines and its strategic focus on expanding its international footprint, particularly in regulated markets. The firm’s robust pipeline of products, coupled with its strengths in key therapeutic segments, positions it well for future growth. Furthermore, Torrent’s consistent financial performance and prudent management practices reflect the core principles of value investing, making it an attractive consideration for those looking to invest in a company that not only prioritizes profitability but also contributes positively to global healthcare outcomes. As the pharmaceutical industry continues to evolve, Torrent Pharmaceuticals Ltd. stands ready to navigate the complexities ahead while delivering sustained shareholder value.
Torrent Pharmaceuticals Ltd. is a prominent Indian pharmaceutical company primarily engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The core business segments of Torrent Pharmaceuticals can be categorized as follows:
-
Branded Generics: This segment forms the backbone of Torrent's business. The company markets a wide array of branded generics across various therapeutic categories, including cardiology, psychiatry, neurology, gastroenterology, and more. This segment is crucial in both domestic and international markets.
-
Generic Pharmaceuticals: Torrent also produces generic medications, which are typically more affordable alternatives to branded drugs. This segment includes a variety of active pharmaceutical ingredients (APIs) and formulations that serve both the domestic and international markets.
-
Over-the-Counter (OTC) Products: In addition to prescription medications, Torrent offers a range of OTC products aimed at consumer health. These products are designed for self-medication and are marketed directly to consumers without a prescription.
-
Research and Development (R&D): Torrent invests significantly in R&D to innovate and improve its existing product lines as well as to develop new drug formulations. This segment is essential for maintaining a competitive edge and ensuring compliance with global health standards.
-
International Operations: Torrent has a significant presence in various international markets, particularly in the U.S., Europe, and emerging markets. This segment helps diversify the company’s revenue sources and reduces dependence on the domestic pharmaceutical market.
-
Therapeutic Segments: The company focuses on numerous therapeutic areas, including but not limited to:
- Cardiovascular
- Central Nervous System (CNS)
- Gastroenterology
- Women's Healthcare
- Anti-infectives
-
Biosimilars: This is an emerging segment for Torrent, wherein the company is actively involved in developing biosimilar products. These products are biopharmaceuticals that are highly similar to already approved reference products and can offer cost-effective treatment options.
Torrent Pharmaceuticals’ strategic focus on innovation, quality, and expanding its product portfolio positions it well in the competitive pharmaceutical landscape. Each of these segments contributes to the overall growth and sustainability of the company.
Torrent Pharmaceuticals Ltd has several unique competitive advantages that distinguish it from its rivals in the pharmaceutical industry:
-
Strong Product Portfolio: Torrent has a diverse portfolio that includes a wide range of therapeutic categories, enabling it to cater to various market segments. Its focus on niche therapeutic areas, such as cardiovascular, central nervous system, and gastrointestinal medications, helps it establish a strong market presence.
-
Research and Development (R&D) Capabilities: Torrent invests significantly in R&D, which allows it to develop innovative and high-quality products. This enhances its ability to bring differentiated products to market quickly, giving it a competitive edge.
-
Strategic Acquisitions: The company has a history of strategic acquisitions that bolster its product line and market share. For example, acquiring companies or products can enhance operational efficiencies and expand its geographical reach.
-
Regulatory Compliance and Quality Assurance: Torrent is known for its adherence to high standards of quality and regulatory compliance. This builds trust with healthcare professionals and patients, providing them with confidence in the safety and efficacy of its products.
-
Strong Distribution and Market Access: The company has established robust distribution networks and market access strategies, allowing it to efficiently reach healthcare providers and consumers. This capability is essential for achieving higher sales and market penetration.
-
Competitive Pricing Strategy: Torrent often competes on price without compromising quality, which enables it to capture cost-sensitive segments of the market while maintaining profitability.
-
Global Presence: With operations in multiple countries, including a strong presence in emerging markets, Torrent capitalizes on global opportunities for growth. This geographic diversity helps mitigate risks associated with reliance on a single market.
-
Experienced Management Team: The leadership team's experience and strategic vision contribute to the company's ability to navigate challenges and seize new opportunities, vital for long-term growth and sustainability.
-
Focus on Generic Drugs: Torrent has a strong portfolio of generic medications, benefiting from the growing demand for cost-effective treatment options. This focus helps it capture market share in a competitive sector.
These competitive advantages, combined with a solid operational framework, allow Torrent Pharmaceuticals to effectively differentiate itself and maintain a significant position in the competitive pharmaceutical landscape.
Torrent Pharmaceuticals Ltd, like many companies in the pharmaceutical sector, faces several risks and challenges that could impact its operations and growth prospects in the near future. Here are some of the key risks and challenges:
-
Regulatory Compliance:
- The pharmaceutical industry is heavily regulated, and Torrent must comply with stringent regulations from various health authorities (e.g., FDA, EMA). Any changes in regulations or failure to meet compliance requirements could result in delays or bans on product launches.
-
Intellectual Property Issues:
- Patent expirations on key drugs can lead to increased competition from generic manufacturers. Torrent must continuously innovate and develop new patents to maintain its market position.
-
Market Competition:
- The company faces intense competition from both domestic and international pharmaceutical companies. This includes competition from generic drug manufacturers, which can erode market share and pricing power.
-
Supply Chain Disruptions:
- Global events such as pandemics, geopolitical tensions, and trade disputes can disrupt the supply chain, affecting the availability of raw materials and impacting production.
-
Pricing Pressure:
- Increasing pressure from healthcare providers, insurers, and governments to reduce drug prices can impact profitability. Negotiations around drug pricing and reimbursement can also pose significant challenges.
-
R&D Challenges:
- The pharmaceutical sector relies heavily on research and development. High costs and risks associated with drug development, including clinical trial failures, can impact financial performance.
-
Public Sentiment and Trust:
- Negative publicity related to drug safety, efficacy, or ethical issues can damage a pharmaceutical company’s reputation and impact sales. Maintaining public trust is critical for long-term success.
-
Technological Advancements:
- Rapid advancements in technology, such as personalized medicine and digital health, may necessitate adaptations in business strategy. Companies failing to keep pace with technological changes risk becoming obsolete.
-
Economic Downturns:
- Economic challenges, such as recessions or reduced healthcare spending, can impact the overall market for pharmaceuticals and affect sales volumes.
-
Geopolitical Risks:
- Political instability in key markets, trade tensions, or changes in government policy can present risks to the company's international operations.
-
COVID-19 Aftermath:
- The long-term impacts of the COVID-19 pandemic on healthcare systems, consumer behavior, and regulatory frameworks are still evolving, presenting uncertainty for pharmaceutical companies.
Overall, while Torrent Pharmaceuticals has the potential for growth, it must proactively manage these risks and challenges to ensure sustainable operations and profitability in the competitive pharmaceutical landscape.
Revenue & Expenses Breakdown
Torrent Pharmaceuticals Ltd
Balance Sheet Decomposition
Torrent Pharmaceuticals Ltd
Current Assets | 58.8B |
Cash & Short-Term Investments | 14.8B |
Receivables | 17.9B |
Other Current Assets | 26.1B |
Non-Current Assets | 92.1B |
Long-Term Investments | 650m |
PP&E | 36.3B |
Intangibles | 46.7B |
Other Non-Current Assets | 8.4B |
Current Liabilities | 48.5B |
Accounts Payable | 21.9B |
Other Current Liabilities | 26.6B |
Non-Current Liabilities | 27.4B |
Long-Term Debt | 14.7B |
Other Non-Current Liabilities | 12.6B |
Earnings Waterfall
Torrent Pharmaceuticals Ltd
Revenue
|
112.2B
INR
|
Cost of Revenue
|
-27.5B
INR
|
Gross Profit
|
84.8B
INR
|
Operating Expenses
|
-56.9B
INR
|
Operating Income
|
27.8B
INR
|
Other Expenses
|
-9.8B
INR
|
Net Income
|
18B
INR
|
Free Cash Flow Analysis
Torrent Pharmaceuticals Ltd
INR | |
Free Cash Flow | INR |
In Q2 FY25, Torrent Pharma reported a 9% revenue growth to INR 2,889 crores, with branded businesses driving 74% of revenue. Notably, the India segment saw a healthier 13% growth. Operating EBITDA rose by 14% to INR 939 crores, yielding a margin of 32.5%. The company anticipates recovery of insulin revenue shortfall in Q4, ensuring no annual impact. Looking ahead, Torrent expects a sustainable EBITDA margin improvement of 50-100 basis points annually and aims for continued double-digit growth in Brazil. However, U.S. revenue growth remains modest, projected to stabilize in the coming years with profitability targeted within three years.
What is Earnings Call?
TORNTPHARM Profitability Score
Profitability Due Diligence
Torrent Pharmaceuticals Ltd's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
Score
Torrent Pharmaceuticals Ltd's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
TORNTPHARM Solvency Score
Solvency Due Diligence
Torrent Pharmaceuticals Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Torrent Pharmaceuticals Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TORNTPHARM Price Targets Summary
Torrent Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for TORNTPHARM is 3 552.51 INR with a low forecast of 2 385.62 INR and a high forecast of 4 236.75 INR.
Dividends
Current shareholder yield for TORNTPHARM is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
TORNTPHARM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Torrent Pharmaceuticals Ltd. engages in the research, development, manufacture, and marketing of generic pharmaceutical formulations. The company is headquartered in Ahmedabad, Gujarat and currently employs 12,910 full-time employees. The firm is engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. The company operates in the therapeutic segments of cardiovascular (CV), gastrointestinal (GI), central nervous system (CNS), and vitamins minerals nutritionals (VMN). The company also has presence in therapeutic areas, such as anti-epileptic, anti-diabetic, anti-cancer, anti-acne, corticosteroids and cosmeceuticals. The company has developed complex formulations for global markets based on oral solids, injections, inhalation technologies, long-acting depot injections ophthalmic, nasal, semisolids for external applications and multi-particulate extended-release oral systems. The firm is developing various in-house new chemical entities (NCE) in the areas of metabolic, cardiovascular, gastrointestinal, dermatological and respiratory disorders. The company has a presence across more than 40 countries.
Contact
IPO
Employees
Officers
The intrinsic value of one TORNTPHARM stock under the Base Case scenario is 1 952.77 INR.
Compared to the current market price of 3 167.1 INR, Torrent Pharmaceuticals Ltd is Overvalued by 38%.